Tarsus Pharmaceuticals, Inc. TARS Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $451.36M+147% | $182.95M+949% | $17.45M-32.4% | $25.82M-54.7% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $64.32M+20.5% | $53.39M+6.1% | $50.31M+18.0% | $42.62M+2.2% | ||
| $427.32M+80.1% | $237.31M+118% | $108.7M+142% | $44.95M— | ||
| $522.33M+72.1% | $303.52M+89.0% | $160.61M+81.4% | $88.53M— | ||
| -$70.97M+41.1% | -$120.57M+15.8% | -$143.16M-128% | -$62.71M-416% | ||
| -15.7%+50.2pp | -65.9%+755pp | -820.5%-578pp | -242.9%-222pp | ||
| $8.94M+13.8% | $7.85M+135% | $3.35M+53.1% | $2.19M+13,556% | ||
| $6.61M+31.8% | $5.02M-31.0% | $7.27M+1,077% | $617K+138% | ||
| -$64.36M+44.3% | -$115.55M+15.0% | -$135.89M-119% | -$62.1M-351% | ||
| —— | $0— | $0+100% | -$4K-107% | ||
| -$66.42M+42.5% | -$115.55M+15.0% | -$135.89M-119% | -$62.09M-349% | ||
| -14.7%+48.4pp | -63.2%+716pp | -778.9%-538pp | -240.5%-216pp | ||
| -$1.61+47.9% | -$3.09+32.8% | -$4.60-80.4% | -$2.55-254% | ||
| -$69.27M+42.0% | -$119.37M+16.1% | -$142.33M-128% | -$62.39M-427% | ||
| -15.3%+49.9pp | -65.2%+751pp | -815.8%-574pp | -241.7%-221pp | ||
| -$70.97M+41.1% | -$120.57M+15.8% | -$143.16M-128% | -$62.71M-416% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s revenue?
- Tarsus Pharmaceuticals, Inc. (TARS) generated $535.1M in revenue over the trailing twelve months, up 129.0% year over year.
- Is Tarsus Pharmaceuticals, Inc. profitable?
- Tarsus Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $48.3M over the trailing twelve months, a -9.0% net margin.
- What are Tarsus Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 42.7% and operating margin is -9.5%, with a -9.0% net margin.
- What is Tarsus Pharmaceuticals, Inc.'s earnings per share?
- Tarsus Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.13.
- Where does Tarsus Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
